Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Targeted Therapies for B-cell Leukemia and Lymphoma
share announcement

Targeted Therapies for B-cell Leukemia and Lymphoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 853

Special Issue Editors

Prof. Dr. Tadeusz Robak

E-Mail Website
Guest Editor
1. Department of Hematology, Medical University of Lodz, 93-510 Lodz, Poland
2. Department of General Hematology, Copernicus Memorial Hospital, 93-510 Lodz, Poland
Interests: leukemia; lymphoma; multiple myeloma; autoimmune cytopenias; targeted drugs
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Iwona Hus

E-Mail Website
Guest Editor
National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
Interests: chronic lymphocytic leukemia; lymphoma; multiple myeloma; novel drugs

Special Issue Information

Dear Colleagues,

Recent years have brought unprecedented progress in the treatment of leukemia and lymphoma. The chemotherapy that used to be the mainstay of anticancer therapy is being increasingly replaced by novel targeted therapies in both lymphoid and myeloid malignancies. Currently, two main strategies are in use, viz., immunotherapy and targeted small agent therapy, with more being approved and even more in clinical and preclinical development. Each tool appears to have its use, with immunotherapy being the most effective treatment for B-cell lymphoma and targeted small agents for indolent B-cell malignancies. In recent years, the treatment of B-cell lymphoid malignancies has been greatly improved by the development of targeted drugs, particularly Bruton’s turosine kinase (BTK) inhibitors, phosphoinositide 3-kinases (PI3K) inhibitors and the BCL-2 inhibitor venetoclax. BTK inhibitors can be irreversible, covalently binding to cysteine 481 in the ATP binding pocket of BTK, or reversible, which bind BTK non-covalently and do not require C481 for their activity. Currently, the first-generation BTK inhibitor ibrutinib and the second-generation inhibitors acalabrutinib and zanubrutinib are approved for the treatment of B-cell malignancies. Immunotherapy strategies encompass a range of different monoclonal antibody-based therapies such as antibody–drug conjugates (ADCs) or bispecific antibodies (BITEs), as well as chimeric antigen receptor (CAR) T-cell therapy, which has revolutionized the treatment of acute lymphoblastic leukemia, aggressive B-cell lymphoma and, more recently, multiple myeloma.

This Special Issue will include both original and review articles on approved targeted therapies, as well as emerging therapies for B-cell leukemia and lymphoma that are currently in preclinical and clinical development.

Prof. Dr. Tadeusz Robak
Prof. Dr. Iwona Hus
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • leukemia 
  • lymphoma 
  • targeted therapies 
  • monoclonal antibodies 
  • antibody–drug conjugates (ADCs) 
  • bispecific antibodies (BITEs) 
  • CAR-T-cell therapy 
  • tyrosine kinase inhibitors 
  • Bcl-2 inhibitors

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 2119 KiB  
Communication
Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population
by Stefano Molica, Tait D. Shanafelt, David Allsup and Diana Giannarelli
Cancers 2024, 16(6), 1085; https://doi.org/10.3390/cancers16061085 - 07 Mar 2024
Viewed by 662
Abstract
To assess the impact of first-line treatment with targeted agents (TAs) or fludarabine, cyclophosphamide, and rituximab (FCR)-based chemo-immunotherapy (CIT) on overall survival (OS) compared to age- and sex-matched individuals in the general population, we conducted an aggregated analysis of phase 3 clinical trials, [...] Read more.
To assess the impact of first-line treatment with targeted agents (TAs) or fludarabine, cyclophosphamide, and rituximab (FCR)-based chemo-immunotherapy (CIT) on overall survival (OS) compared to age- and sex-matched individuals in the general population, we conducted an aggregated analysis of phase 3 clinical trials, including the two FLAIR sub-studies, ECOG1912, and CLL13 trials. The restricted mean survival time (RMST), an alternative measure in outcome analyses capturing OS changes over the entire history of the disease, was used to minimize biases associated with the short follow-up time of trials. Patients treated with TAs demonstrated a higher 5-year RMST (58.1 months; 95% CI: 57.4 to 58.8) compared to those treated with CIT (5-year RMST, 56.9 months; 95% CI: 56.7–58.2). Furthermore, the OS comparison of treatment groups with the AGMGP suggests that TAs may mitigate the impact of CLL on OS during the first five years post-treatment initiation. In summary, the 5-year RMST difference was −0.4 months (95% CI: −0.8 to 0.2; p = 0.10) when comparing CLL patients treated with TAs to the Italian age- and gender-matched general population (AGMGP). A similar trend was observed when CLL patients treated with TAs were compared to the US AGMGP (5-year RMST difference, 0.3 months; 95% CI: −0.1 to 0.9; p = 0.12). In contrast, CLL patients treated with FCR exhibited sustained OS differences when compared to both the Italian cohort (5-year RMST difference: −1.6 months; 95% CI: −2.4 to −0.9; p < 0.0001) and the US AGMGP cohort (5-year RMST difference: −0.9 months; 95% CI: −1.7 to −0.2; p = 0.015). Although these results support TAs as the preferred first-line treatment for younger CLL patients, it is crucial to acknowledge that variations in patient selection criteria and clinical profiles across clinical trials necessitate a cautious interpretation of these findings that should be viewed as directional and hypothesis-generating. A longer follow-up is needed to assess the survival improvement of younger CLL patients treated with TAs relative to the AGMGP. Full article
(This article belongs to the Special Issue Targeted Therapies for B-cell Leukemia and Lymphoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop